During Thursday’s Current trade, Shares of Micrel, Incorporated (NASDAQ:MCRL), gain 0.14% to $13.94.
Micrel, Incorporated (MCRL) declared that it intends to delist Micrel’s common stock from NASDAQ in connection with the pending acquisition of Micrel by Microchip Technology Incorporated (“Microchip”), by means of a first step merger of Mambo Acquisition Corp., a California corporation and wholly owned partner of Microchip, with and into Micrel (the “Merger”), with Micrel surviving the Merger as a wholly owned partner of Microchip (the “Interim Surviving Company”), and a second step merger of the Interim Surviving Company into Mambo Acquisition LLC, with Mambo Acquisition LLC surviving the second step merger as a wholly owned partner of Microchip. The first step merger is predictable to be accomplished on August 3, 2015, subject to adoption of the merger agreement by Micrel’s shareholders and certain other conditions contained in the merger agreement.
In accordance with the rules of the Securities and Exchange Commission and NASDAQ, Micrel has offered written notice to NASDAQ of its intent to delist. Micrel intends to file a Form 25 with the Securities and Exchange Commission on July 27, 2015, to effect the delisting. By operation of law, the delisting will be effective ten days after the filing of the Form 25. Micrel reserves the right to delay the filing of the Form 25 or subsequently withdraw or amend any formerly filed Form 25. If the first step merger is accomplished preceding to the effective date of the delisting, trading of Micrel common stock on NASDAQ will be suspended at that time. Offered that the requirements for deregistration are met, in due course, Micrel intends to file a Form 15 with the Securities and Exchange Commission under the Exchange Act of 1934, as amended (the “Exchange Act”), requesting the deregistration of the Shares under Section 12(g) of the Exchange Act and the suspension of Micrel’s reporting obligations under Section 15(d) of the Exchange Act. As of the date of the filing of the Form 15, the obligation of the Company and its auxiliaries to file reports under the Exchange Act, counting Forms 10-K, 10-Q and 8-K, will be right away suspended. Other filing requirements will terminate upon the effectiveness of the deregistration under Section 12(g) of the Exchange Act, which is predictable to occur 90 days after the filing of the Form 15.
Micrel, Incorporated, together with its auxiliaries, designs, develops, manufactures, and markets analog, mixed-signal, and digital semiconductor devices primarily in North America, Asia, and Europe. It offers power conversion products, counting LDOs, DC/DC converters, analog power switches, PMICs, solid state lighting products, and FET drivers; supervisory and reference products that protect, monitor, and enhance the interface of circuitry around microcontroller and processor circuits; and general linear parts, such as op amps, thermal measurement devices, timers, and other general devices.
Shares of Fibrocell Science Inc (NASDAQ:FCSC), inclined 0.31% to $6.55, during its current trading session.
Fibrocell Science, Inc., (FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, declared the pricing of an underwritten public offering of 2.6 million shares of its common stock at a price of $5.80 per share. In addition, Fibrocell has granted the underwriters a 30-day option to purchase up to an additional 0.4 million shares of common stock.
All shares in the offering are being sold by Fibrocell, with predictable net proceeds to Fibrocell of about $13.6 million, after deducting underwriting discounts and commissions and estimated offering expenses and not counting any proceeds to be received by Fibrocell if the underwriters were to exercise the 30-day option. The offering is predictable to close on or about July 27, 2015, subject to satisfaction of customary closing conditions.
Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring.
Capstone Turbine Corporation (NASDAQ:CPST), during its Thursday’s current trading session gained 1.62% to $0.365.
Capstone Turbine Corporation (CPST), the world’s leading clean technology manufacturer of microturbine energy systems, will release financial results for the first quarter of fiscal year 2016 ended June 30, 2015 at 1:45 p.m. Pacific Time (4:45 p.m. Eastern) on August 6, 2015.
Capstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. It offers microturbine units, subassemblies, components, and various accessories for applications, counting cogeneration comprising combined heat and power (CHP) and integrated CHP, in addition to combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply.
Finally, Invesco Ltd. (NYSE:IVZ), decreased -0.44%, to $38.33.
Canada has received securityholder approval to merge Trimark North American Endeavour Class into Trimark U.S. Companies Class. The merger is predictable to be effective after the close of business on or about August 7, 2015.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
